Reference health
A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics
45/45 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
8 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 45 checked references that resolve
resolves10.1007/s00520-015-2809-3
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
resolves10.1007/s00520-010-0915-9
Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population
resolves10.1016/j.ejphar.2013.09.073
International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice
resolves10.1007/s00520-010-1003-x
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art
resolves10.1200/JCO.2010.34.4614
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
resolves10.1093/annonc/mdq194
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
resolves10.1093/annonc/mdj078
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
resolves10.1093/annonc/mds021
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
resolves10.1200/JOP.2012.000816
Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study
resolves10.1002/cncr.27899
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer
resolves10.18553/jmcp.2012.18.5.385
Assessment of the Relationship Between Adherence with Antiemetic Drug Therapy and Control of Nausea and Vomiting in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy
resolves10.1007/s00520-014-2325-x
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers
resolves10.1111/febs.12260
Modulating the endocannabinoid system in human health and disease – successes and failures
resolves10.1056/NEJM197510162931603
Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy
resolves10.1111/j.1365-2354.2008.00917.x
Therapeutic use of<i>Cannabis sativa</i>on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis
resolves10.1136/bmj.323.7303.16
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
resolves10.6004/jnccn.2012.0048
Cannabinoids in the Treatment of Chemotherapy-Induced Nausea and Vomiting
resolves10.1002/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4
A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy
resolves10.1111/j.1365-2125.2012.04164.x
Novel Δ<sup>9</sup>‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
resolves10.1093/jat/29.8.782
Simultaneous and Sensitive Analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in Plasma after Oral Application of Small Doses of THC and Cannabis Extract
resolves10.1016/j.euroneuro.2014.06.007
Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: A randomized controlled trial
resolves10.1016/S0304-3959(03)00163-5
The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions
resolves10.1002/j.1552-4604.1981.tb02594.x
The Metabolism of Δ<sup>9</sup>‐Tetrahydrocannabinol and Related Cannabinoids in Man
resolves10.1002/jcph.90
Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ<sup>9</sup>‐THC in Cannabis Users
resolves10.1093/jat/16.5.276
Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana*
resolves10.1038/clpt.1980.181
Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking
resolves10.1373/clinchem.2015.238287
Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol
resolves10.1002/j.1552-4604.1981.tb02593.x
Do Plasma Concentrations of Δ<sup>9</sup>‐Tetrahydrocannabinol Reflect the Degree of Intoxication?
resolves10.1093/gerona/57.11.M722
Prevalence and Risk Factors for Falls in an Older Community-Dwelling Population
resolves10.1056/NEJMp1500043
Medical Marijuana's Public Health Lessons — Implications for Retail Marijuana in Colorado
resolves10.1002/cncy.21524
Medical marijuana: Hints of headway? Despite a conflicted regulatory landscape, support for medical marijuana is growing amid increasing evidence of potential benefits
resolves10.1155/2015/707596
The Cannabis Dilemma: A Review of Its Associated Risks and Clinical Efficacy
The 8 references without a DOI — listed, not checked
no DOI — not checkedNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis. (2016). Accessed 5 May 2016
no DOI — not checkedMarinol® (dronabinol) capsules [package insert] (2017) AbbVie Inc., North Chicago
no DOI — not checkedCesamet® (nabilone) capsules for oral administration [package insert] (2013) Meda Pharmaceuticals, Somerset
no DOI — not checkedSYNDROSTM (dronabinol) oral solution, CX [package insert] (2016) Insys Therapeutics, Inc., Chandler
no DOI — not checkedSmith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 11:CD009464
no DOI — not checkedParikh N, Kramer WG, Khurana V, Cognata Smith C, Vetticaden S (2016) Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clin Pharmacol 8:155–162
no DOI — not checkedJoy J, Watson S, Benson JJ (eds) (1999) Marijuana and medicine: assessing the science base. National Academy Press, Washington, D.C
no DOI — not checkedSlatkin NE (2007) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 5(5 Suppl 3):1–9
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s00280-017-3387-5"><img src="https://citestamp.com/citestamped/10.1007/s00280-017-3387-5/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s00280-017-3387-5)